SG11201912881SA - Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide - Google Patents
Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideInfo
- Publication number
- SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912881SA true SG11201912881SA (en) | 2020-01-30 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912881SA SG11201912881SA (en) | 2017-07-05 | 2018-07-04 | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (enExample) |
| EP (1) | EP3649117B1 (enExample) |
| JP (2) | JP2020525475A (enExample) |
| KR (1) | KR102645911B1 (enExample) |
| CN (1) | CN110831932A (enExample) |
| AU (1) | AU2018296423B2 (enExample) |
| BR (1) | BR112020000099A2 (enExample) |
| CA (1) | CA3067489A1 (enExample) |
| CL (1) | CL2020000002A1 (enExample) |
| EA (1) | EA202090193A1 (enExample) |
| IL (1) | IL271764B2 (enExample) |
| MA (1) | MA50972A (enExample) |
| MY (1) | MY206357A (enExample) |
| PH (1) | PH12020500040A1 (enExample) |
| SG (1) | SG11201912881SA (enExample) |
| UA (1) | UA126582C2 (enExample) |
| WO (1) | WO2019008034A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| EP3577099B1 (en) | 2017-02-06 | 2024-01-24 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| EA202090193A1 (ru) * | 2017-07-05 | 2020-06-03 | Идорсия Фармасьютиклз Лтд | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида |
| CN115103668A (zh) | 2019-12-20 | 2022-09-23 | 爱杜西亚药品有限公司 | 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺的药物组合物 |
| KR20240046879A (ko) * | 2021-08-17 | 2024-04-11 | 한국과학기술원 | Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40281B1 (fr) | 2014-06-03 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
| EP3194374B1 (en) | 2014-09-15 | 2018-08-01 | Idorsia Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| EP3577099B1 (en) | 2017-02-06 | 2024-01-24 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| EA202090193A1 (ru) * | 2017-07-05 | 2020-06-03 | Идорсия Фармасьютиклз Лтд | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида |
-
2018
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA50972A (fr) | 2020-10-14 |
| WO2019008034A1 (en) | 2019-01-10 |
| CA3067489A1 (en) | 2019-01-10 |
| UA126582C2 (uk) | 2022-11-02 |
| US11059803B2 (en) | 2021-07-13 |
| KR20200018698A (ko) | 2020-02-19 |
| CN110831932A (zh) | 2020-02-21 |
| MY206357A (en) | 2024-12-12 |
| EP3649117A1 (en) | 2020-05-13 |
| US20210300894A1 (en) | 2021-09-30 |
| JP2023123679A (ja) | 2023-09-05 |
| IL271764A (en) | 2020-02-27 |
| EP3649117B1 (en) | 2024-10-09 |
| US20200165221A1 (en) | 2020-05-28 |
| US11555025B2 (en) | 2023-01-17 |
| PH12020500040A1 (en) | 2020-10-12 |
| BR112020000099A2 (pt) | 2020-07-07 |
| EA202090193A1 (ru) | 2020-06-03 |
| CL2020000002A1 (es) | 2020-07-31 |
| KR102645911B1 (ko) | 2024-03-08 |
| JP2020525475A (ja) | 2020-08-27 |
| IL271764B2 (en) | 2023-10-01 |
| AU2018296423A1 (en) | 2020-02-20 |
| AU2018296423B2 (en) | 2022-07-28 |
| IL271764B1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271764A (en) | Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| IL274488A (en) | Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| GB201609607D0 (en) | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts | |
| IL275292A (en) | Inhibitors of the integrated stress response pathway | |
| IL257390B (en) | Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors | |
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| IL279151A (en) | Inhibitors of an integrated stress response pathway | |
| IL285675A (en) | Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| LT3448849T (lt) | Indazolo sintezė | |
| IL276977A (en) | Creation of piezoelectric devices | |
| GB201609603D0 (en) | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide | |
| IL266003A (en) | Salts of indazole derivatives and their crystals | |
| LT3099302T (lt) | 2-(tret-butilamino)-4-((1r,3r,4r)-3-hidroksi-4-metilcikloheksilamino)-pirimidin-5-karboksamido kristalinės formos | |
| ZA201907022B (en) | Reduction of regenerator clogging | |
| ZA202003028B (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
| HK40025427A (en) | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| SG11202103847QA (en) | Estimation of asymmetric aberrations | |
| IL261445A (en) | Herbicidal compositions containing 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1h-tetrazole-5-yl)-4-(trifluoromethyl)benzamide | |
| PL3643704T3 (pl) | Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu | |
| EP3687987A4 (en) | CRYSTALLINE FORMS OF LENALIDOMIDE | |
| IT201700050223A1 (it) | Procedimento per la preparazione di dexlansoprazolo cristallino | |
| IL249496A0 (en) | Improved process for the preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-h4,2,1-1-triazol-3-yl)benzoyl azide | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| GB201705905D0 (en) | Pack of disposable wipes | |
| GB201600013D0 (en) | Domperidone medicine intermediate 1-(30chloropropyl)-benzimidazol-2-one synthesis method |